Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Sasa H et al. | Hepatic extraction of tacrolimus in rats with experimental liver diseases. | 1998 | Biol. Pharm. Bull. | pmid:9657047 |
Le Bihan S et al. | Calcium/calmodulin kinase inhibitors and immunosuppressant macrolides rapamycin and FK506 inhibit progestin- and glucocorticosteroid receptor-mediated transcription in human breast cancer T47D cells. | 1998 | Mol. Endocrinol. | pmid:9658403 |
Fujino T et al. | The immunosuppressive compound FK506 does not affect expulsion of Echinostoma trivolvis in C3H mice. | 1998 | Parasitol. Res. | pmid:9660146 |
McBride WJ et al. | Allogeneic fetal intestinal transplantation with FK506 immunosuppression. | 1998 | J. Pediatr. Surg. | pmid:9660232 |
Bader G et al. | Reduction of cyclosporine-induced gingival overgrowth following a change to tacrolimus. A case history involving a liver transplant patient. | 1998 | J. Periodontol. | pmid:9660343 |
Tsujikawa A et al. | Tacrolimus (FK506) attenuates leukocyte accumulation after transient retinal ischemia. | 1998 | Stroke | pmid:9660400 |
Lai MM et al. | Cain, a novel physiologic protein inhibitor of calcineurin. | 1998 | J. Biol. Chem. | pmid:9660798 |
Nagayasu T et al. | Expression of proliferating cell nuclear antigen in bronchial epithelium after lung transplantation in the rat. | 1998 | J. Heart Lung Transplant. | pmid:9662091 |
Stockwell BR and Schreiber SL | TGF-beta-signaling with small molecule FKBP12 antagonists that bind myristoylated FKBP12-TGF-beta type I receptor fusion proteins. | 1998 | Chem. Biol. | pmid:9662508 |
Kokado Y et al. | Low-dose tacrolimus (FK506)-based immunosuppressive protocol in living donor renal transplantation. | 1998 | Transpl. Int. | pmid:9664945 |
Hauser IA and Neumayer HN | Tacrolimus and cyclosporine efficacy in high-risk kidney transplantation. European Multicentre Tacrolimus (FK506) Renal Study Group. | 1998 | Transpl. Int. | pmid:9664948 |
Morris-Stiff G et al. | Conversion of renal transplant recipients from cyclosporin to low-dose tacrolimus for refractory rejection. | 1998 | Transpl. Int. | pmid:9664949 |
Morris-Stiff G et al. | Conversion of renal transplant recipients from cyclosporin (neoral) to tacrolimus (prograf) for haemolytic uraemic syndrome. | 1998 | Transpl. Int. | pmid:9664954 |
Kyo M et al. | Morphological findings in non-episode biopsies of kidney transplant allografts treated with FK506 or cyclosporine. | 1998 | Transpl. Int. | pmid:9664955 |
Hernández-Herrera G et al. | Tacrolimus rescue therapy for cyclosporine-induced nephrotoxicity. | 1998 | Transpl. Int. | pmid:9664956 |
Margarit C et al. | Efficacy and safety of oral low-dose tacrolimus treatment in liver transplantation. | 1998 | Transpl. Int. | pmid:9664992 |
Pou L et al. | Influence of posttransplant time on dose and concentration of tacrolimus in liver transplant patients. | 1998 | Transpl. Int. | pmid:9664994 |
Reggiani P et al. | Rescue FK506 early conversion for refractory rejection after pediatric liver transplantation: experience in 20 children. | 1998 | Transpl. Int. | pmid:9664995 |
Jara P et al. | Tacrolimus for steroid-resistant liver rejection in children. | 1998 | Transpl. Int. | pmid:9664996 |
Horimoto H et al. | Transplantation tolerance by a combined therapy with sulfatide, anti-LFA-1/ICAM-1 monoclonal antibodies and FK506 in rat cardiac transplantation. | 1998 | Transpl. Int. | pmid:9665003 |